A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Muzumdar, Sonal; Radfar, Arash; Payette, Michael
• Is Part Of: Journal of psoriasis and psoriatic arthritis. Volume 6:Issue 1(2021)
• Page Start: 16
• Page End: 18
• Publication Date: 2021-01
• Subjects: psoriasis -- Grover's disease -- brodalumab -- adverse reaction; Psoriasis -- Periodicals; Psoriasis -- Treatment -- Periodicals; Psoriatic arthritis -- Periodicals; Psoriatic arthritis -- Treatment -- Periodicals; Electronic journals; 616.722
• DOI: 10.1177/2475530320970530
• Languages: English
• ISSNs: 2475-5303

Abstract

Background: Grover's disease has been associated with a number of medications including sulfadoxine-pyrimethamine, recombinant interleukin (IL)-4, ipilimumab, and BRAF inhibitors. To our knowledge, Grover's disease has not been reported in association with interleukin-17 inhibitors. Case Description: A 47-year-old female with plaque psoriasis developed Grover's disease 3 months following initiation of brodalumab. Discontinuation of brodalumab and initiation of certolizumab pegol and methotrexate led to resolution of her rash. Conclusion: This case highlights Grover's disease as a potential adverse effect of brodalumab therapy. In patients who develop Grover's disease with brodalumab, modification of therapy may be considered due to the bothersome nature of the rash.